Skip to main content
. 2018 Aug 7;16(4):2909–2916. doi: 10.3892/etm.2018.6586

Figure 1.

Figure 1.

FGFR1 inhibitor AZD4547 attenuates LPS-induced HSCs activation. (A) Chemical structures and FGFR1-inhibitory IC50 values of AZD4547. HSCs were pretreated with AZD4547 (AZD, 2.5, 5 µM) for 1 h, and then exposed to LPS (100 ng/ml) for the indicated times. (B) Exposure to LPS for 15 min. p-FGFR1 levels detected by western blotting (WB). (C) Exposure to LPS for 24 h. The cell viability of HSCs detected by MTT assay. (D) Exposure to LPS for 6 h, the mRNA levels of TGF-β, col-1, and α-SMA were detected by RT-qPCR and normalised by β-actin. Incubation with LPS for 24 h. (E) The levels of TGF-β, Col-1 and α-SMA in cell lysates were detected by WB. (F and G) Immunofluorescence staining of HSCs for Col-1 (red), and α-SMA (red) in LPS-treated cells pretreated with AZD4547 prior to LPS exposure (blue=DAPI). Representative micrographs are shown (*P<0.05, **P<0.01, ***P<0.001, vs. Ctrl group; #P<0.05, ##P<0.01, ###P<0.001, vs. LPS group).